• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

byConstance Wu
November 28, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Higher body mass index associated with improved cystic fibrosis-related clinical outcomes

Sweat chloride levels predict future cystic fibrosis diagnosis in those with inconclusive diagnosis at birth

Elexacaftor-tezacaftor-ivacaftor is efficacious in treating cystic fibrosis patients with Phe508del-minimal function genotypes

1. In this multicenter, phase 3 study of cystic fibrosis patients who were previously unresponsive to modulator regimens, triple-combination therapy with the next-generation corrector elexacaftor resulted in a significantly improved percentage of predicted forced expiratory volume in one second versus placebo after 4 and 24 weeks.

2. Improvements were also shown in sweat chloride concentration, the rate of pulmonary exacerbations, and the respiratory domain score on the Cystic Fibrosis Questionnaire-Revised.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While hundreds of disease-causing mutations have been discovered for cystic fibrosis, the vast majority of people with the condition exhibit a three base deletion resulting in the absence of a phenylalanine residue (Phe508del) that is essential for intracellular trafficking and native stability of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Concurrent use of CFTR correctors and potentiators has been effective for patients possessing two Phe508del alleles but markedly less so for those with only one copy in addition to a second mutation that is unresponsive to modulator therapy (minimal function). This phase 3 study tested the effects of the triple-combination regimen of the next-generation corrector elexacaftor, the corrector tezacaftor, and the potentiator ivacaftor on CF patients with a single Phe508del allele, finding that treatment with these modulators resulted in significant improvements in forced expiratory volume in one second (FEV1) versus placebo. Patients who received elexacaftor-tezacaftor-ivacaftor treatment also reported dramatic improvements in quality of life based on the Cystic Fibrosis Questionnaire-Revised (CFQ-R) and had a significantly lower risk of pulmonary exacerbations. Adverse events were generally mild to moderate and rarely resulted in discontinuation of treatment. This study was bolstered by high adherence as well as stratification by numerous factors including percentage of predicted FEV1, age, and sex. Additionally, findings were supported by a concurrent trial that demonstrated similar outcomes in homozygous Phe508del patients. While this modulation is likely to benefit a large portion of the CF population, further research is still necessary to extend these benefits to younger children or those with less common responsive mutations.

Click here to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cystic fibrosiselexacaftorFEVivacaftortezacaftor
Previous Post

Daily colchicine after myocardial infarction lowers risk of subsequent event

Next Post

The Relationship between Health Care Provider Burnout and Quality of Patient Care

RelatedReports

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Chronic Disease

Higher body mass index associated with improved cystic fibrosis-related clinical outcomes

March 7, 2022
Higher sodium intake linked to more aggressive multiple sclerosis
Chronic Disease

Sweat chloride levels predict future cystic fibrosis diagnosis in those with inconclusive diagnosis at birth

November 17, 2021
Significant number of wrong-patient errors in radiology reports
Chronic Disease

Elexacaftor-tezacaftor-ivacaftor is efficacious in treating cystic fibrosis patients with Phe508del-minimal function genotypes

November 23, 2019
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Defining airflow obstruction as FEV1:FVC of less than 0.70 optimal compared to other fixed thresholds for COPD

June 27, 2019
Next Post
Use of plant-based therapies and menopausal symptoms

The Relationship between Health Care Provider Burnout and Quality of Patient Care

#VisualAbstract: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

#VisualAbstract: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.